Jessica N. Abraham | Designer. Writer. Publicist.

19+ Years of Expertise in Digital Marketing, Social Branding and Public Relations.

  • Home
  • Contact
  • About
  • Home
  • Contact
  • About

No Widgets found in the Sidebar Alt!

  • Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited. Cardiologist Dr. Joshua Hare is one of those scientists, and he’s both the co-founder and chief scientific officer of Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. He’s also credited with helping to pioneer the use of stem cells as medicine for the human heart and regularly explores a future where regenerative medicine can prolong human life.
    Benzinga,  Biotechnology,  Health,  Nature,  Regenerative Medicine

    Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It

    June 15, 2022 /

    Originally Published on Benzinga Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited. Cardiologist Dr. Joshua Hare is one of those scientists, and he’s both the co-founder and chief scientific officer of Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. He’s also credited with helping to pioneer the use of stem cells as medicine for the human heart and regularly explores a future where regenerative medicine can prolong human life. The global regenerative medicine market  is estimated to reach $6.49 billion in 2027, up 9.3% from $3.05 billion in 2019. …

    read more
    Jessica N. Abraham Comments Off on Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It

    You May Also Like

    All Electric Race Series, Ferrari, Tesla, Worksport, Terravis Energy, Polaris, KULR, Greenland Technologies, KULR, Phoenix Startups, Arizona Startups, StartEngine Startups, Battle Approved Motors, The Battle Ground, BAM, Chris James, Racing, Electric Vehicles, EVs, UTVs, Utility Terrain Vehicles, ATVs, All Terrain Vehicles, Glamping, Racing, NASCAR,

    What is a UTV, and Why Might Investing in BAM be a Good Idea?

    July 22, 2021
    Amesite, Workforce Development, Workforce optimization, training, simulation

    AI-Driven Platform Enhances Corporate Culture, Brief Teams and Upskills the Workforce

    July 20, 2021
    Clean Energy Mining could be what the battery supply chain needs -- infrastructure planning, infrastructure bill, clean cities

    6 Companies That Could Fix Domestic Battery Supply Problem Using Little To No Emissions In The Mining of Essential Minerals

    June 14, 2022
  • Statera Pharmaceuticals treatment for Covid-19 Long-Haulers
    Health,  Benzinga,  Biotechnology,  Business,  Finance

    Groundbreaking Studies to Be Conducted on the Effectiveness of Short and Long-term COVID-19 Therapies Inhibiting the Progression of SARS-CoV-2

    October 28, 2021 /

    Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Statera Biopharma, Inc. (NASDAQ: STAB) recently announced that it has officially received Institutional Review Board (IRB) approval to conduct a Phase 1 pilot study at Loma Linda University Health to evaluate STAT-205 as a treatment in the mitigation of SARS-CoV-2 progression. STAT-205 is a breakthrough immuno-modulator designed to decrease elevated inflammatory responses that are associated with viral infections and inhibit viral replication in human lung cells. Its efficacy was successfully demonstrated during preclinical in vitro studies, where STAT-205 was able to inhibit the replication of…

    read more
    Jessica N. Abraham Comments Off on Groundbreaking Studies to Be Conducted on the Effectiveness of Short and Long-term COVID-19 Therapies Inhibiting the Progression of SARS-CoV-2

    You May Also Like

    Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited. Cardiologist Dr. Joshua Hare is one of those scientists, and he’s both the co-founder and chief scientific officer of Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. He’s also credited with helping to pioneer the use of stem cells as medicine for the human heart and regularly explores a future where regenerative medicine can prolong human life.

    Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It

    June 15, 2022
    What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?

    What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?

    September 8, 2021
    Biotricity provides remote cardiac monitoring to patients through its biokit and Bioflux services. Biotricity's medtech technologies can be found in Samsung Watch4 devices and as a standalone platform at your local physical or health services provider.

    Biotricity Continues to Transform the Way We Do Health: Medtech Launches New Biokit Solution, Aims at Personal Health Monitoring

    September 15, 2021
  • Business
  • Technology
  • Career Development
  • Education
  • Entertainment
  • Fashion
  • Relationships
  • Tips
  • Travel
Ashe Theme by WP Royal.